Table 3. Anti-HIV Activitya and Cytotoxicityb of Withasteroids 1–13.
| compound | IC50a (CI95%; R2c) μM | CC50b μM | SId |
|---|---|---|---|
| 1 | 12.4 (9.5–16.4; 0.8945) | >100 | >8 |
| 2 | 18.7 (13.6–25.9; 0.8333) | >100 | >5.3 |
| 3 | 76.1 (44.9–143.6; 0.7311) | >100 | >1.3 |
| 4 | 72.7 (49.8–111.3; 0.8528) | >100 | >1.4 |
| 5 | >100 | >100 | |
| 7 | 1.9 (0.8–2.7; 0.778) | 16.0 (8.4–31.4; 0.8139) | 10.6 |
| 8 | 67.9 (46.7–103.2; 0.86) | >100 | >1.5 |
| 9 | 8.9 (6.2–13.1; 0.8256) | >100 | >11.2 |
| 10 | 32.7 (24.8–43.6; 0.834) | >100 | >3.1 |
| 12 | 21.1 (14.9–30.1; 0.8075) | >100 | >4.7 |
| 13 | 1.0 (0.6–1.7; 0.8056) | 15.2 (6.8–35.8; 0.7353) | 15.5 |
| TFVe | 1.7 (1.1–2.5; 0.9387) | >100 | 333 |
a
IC50 (inhibitory concentration 50%) values were calculated using GrapPad Pris software. All values are the mean of at least three independent experiments.
b
CC50 (cytotoxic concentration 50%) values were calculated using GrapPad Pris software. All values are the mean of at least three independent experiments.
c
R2: R squared.
d
SI: selectivity index (CC50/IC50).
e
TFV: tenofovir used as an antiretroviral drug control.